135 related articles for article (PubMed ID: 15938560)
21. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
Tosti A; Iorizzo M; Botta GL; Milani M
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1243-7. PubMed ID: 17062039
[TBL] [Abstract][Full Text] [Related]
22. Pituitary-adrenal axis suppression due to topical steroid administration in an infant.
Atabek ME; Pirgon O; Unal E
Pediatr Int; 2007 Apr; 49(2):242-4. PubMed ID: 17445047
[No Abstract] [Full Text] [Related]
23. Sequelae from inadvertent long-term use of potent topical steroids.
Beer K; Downie J
J Drugs Dermatol; 2007 May; 6(5):550-1. PubMed ID: 17679193
[TBL] [Abstract][Full Text] [Related]
24. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial.
Conrotto D; Carbone M; Carrozzo M; Arduino P; Broccoletti R; Pentenero M; Gandolfo S
Br J Dermatol; 2006 Jan; 154(1):139-45. PubMed ID: 16403107
[TBL] [Abstract][Full Text] [Related]
25. Vitiligo treated with topical clobetasol propionate.
Kumari J
Arch Dermatol; 1984 May; 120(5):631-5. PubMed ID: 6721525
[TBL] [Abstract][Full Text] [Related]
26. Pharmaceutical availability of clobetasol-17-propionate from cream and ointment.
Dyderski S; Grześkowiak E; Szałek E; Mrzygłód A
Acta Pol Pharm; 2001; 58(6):435-8. PubMed ID: 12197615
[TBL] [Abstract][Full Text] [Related]
27. Cushing's syndrome caused by mucosal corticosteroid therapy.
Pramick M; Whitmore SE
Int J Dermatol; 2009 Jan; 48(1):100-1. PubMed ID: 19126065
[No Abstract] [Full Text] [Related]
28. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.
Joly P; Roujeau JC; Benichou J; Delaporte E; D'Incan M; Dreno B; Bedane C; Sparsa A; Gorin I; Picard C; Tancrede-Bohin E; Sassolas B; Lok C; Guillaume JC; Doutre MS; Richard MA; Caux F; Prost C; Plantin P; Chosidow O; Pauwels C; Maillard H; Saiag P; Descamps V; Chevrant-Breton J; Dereure O; Hellot MF; Esteve E; Bernard P
J Invest Dermatol; 2009 Jul; 129(7):1681-7. PubMed ID: 19177141
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of '0.05% Clobetasol + 2.5% zinc sulphate' cream vs. '0.05% Clobetasol alone' cream in the treatment of the chronic hand eczema: a double-blind study.
Faghihi G; Iraji F; Shahingohar A; Saidat A
J Eur Acad Dermatol Venereol; 2008 May; 22(5):531-6. PubMed ID: 18284511
[TBL] [Abstract][Full Text] [Related]
30. Exogenous Cushing Syndrome due to Topical Clobetasone use for Diaper Rash.
Jevalikar G; Sharma O
Indian Pediatr; 2016 Jan; 53(1):76-7. PubMed ID: 26840685
[No Abstract] [Full Text] [Related]
31. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis.
Lowe N; Feldman SR; Sherer D; Weiss J; Shavin JS; Lin YL; Foley V; Soto P
J Dermatolog Treat; 2005 Aug; 16(3):158-64. PubMed ID: 16096182
[TBL] [Abstract][Full Text] [Related]
32. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients.
Sánchez Regaña M; Martín Ezquerra G; Umbert Millet P; Llambí Mateos F
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):573-7. PubMed ID: 16164711
[TBL] [Abstract][Full Text] [Related]
33. Over-the-counter clobetasol propionate.
Otley CC; Sober A
Arch Dermatol; 1994 Jan; 130(1):121. PubMed ID: 8285734
[No Abstract] [Full Text] [Related]
34. Topical Clobetasol: An Overlooked Cause of Cushing Syndrome.
Ghirardo S; De Nardi L; Tommasini A; Barbi E; Tornese G
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2300-2302. PubMed ID: 33902425
[TBL] [Abstract][Full Text] [Related]
35. Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound.
Korting HC
Curr Probl Dermatol; 1993; 21():114-21. PubMed ID: 8299364
[No Abstract] [Full Text] [Related]
36. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
37. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial.
Vena GA; Cassano N; D'Argento V; Milani M
Br J Dermatol; 2006 Feb; 154(2):353-6. PubMed ID: 16433809
[TBL] [Abstract][Full Text] [Related]
38. Adrenal insufficiency secondary to inappropriate oral administration of topical exogenous steroids presenting with hypercalcaemia.
Bhatti RS; Flynn MD
BMJ Case Rep; 2012 Jun; 2012():. PubMed ID: 22729340
[TBL] [Abstract][Full Text] [Related]
39. Exogenous Cushing syndrome due to misuse of potent topical steroid.
Özgüç Çömlek F; Örüm S; Aydın S; Tütüncüler F
Pediatr Dermatol; 2018 Mar; 35(2):e121-e123. PubMed ID: 29315782
[TBL] [Abstract][Full Text] [Related]
40. Side effects of topical glucocorticoids.
Mills CM; Marks R
Curr Probl Dermatol; 1993; 21():122-31. PubMed ID: 8299365
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
